Preclinical studies have shown that various HDAC inhibitors (e.g., PCI-24781, trichostatin A, valproic acid, and vorinostat) in combination with tamoxifen (a selective estrogen receptor (ER) modulator) lead to endocrine sensitivity and increased cell death of breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.